- Home
- PETZ vs CLRB Comparison
PETZ vs CLRB Comparison
Compare PETZ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | CLRB |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.9M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PETZ | CLRB |
|---|---|---|
| Price | $1.16 | $3.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.7K | ★ 44.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.23 |
| 52 Week High | $1.68 | $10.19 |
Technical Indicators
Market Signals| Indicator | PETZ | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 53.69 |
| Support Level | $0.94 | $3.19 |
| Resistance Level | $1.20 | $3.60 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 41.98 | 73.99 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.